Search company, investor...
Ariceum Therapeutics company logo

Ariceum Therapeutics

ariceum-therapeutics.com

Founded Year

2021

Stage

Series A - II | Alive

Total Raised

$51.75M

Last Raised

$24.96M | 1 mo ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+30 points in the past 30 days

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical-stage radiopharmaceutical company focused on the diagnosis and treatment of certain neuroendocrine and other cancers. Ariceum's systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan ("satoreotide") is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumors (NETs) and some other cancers such as small cell lung cancer (SCLC). Storewide is developed as a 'theranostic' pair for the combined diagnosis and targeted radionuclide treatment of these tumors. It serves clients operating in the healthcare sector. The company was founded in 2021 and is based in Berlin, Germany.

Headquarters Location

Robert-Rössle-Straße. 10 Building 79

Berlin, 13125,

Germany

+49 30 9489 3360

Missing: Ariceum Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ariceum Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Ariceum Therapeutics News

UCB, Ariceum Partner to Discover New Modalities for Immune-related Diseases

May 15, 2023

Ariceum to leverage expertise in radiopharmaceuticals and labelling technology to aid UCB's discovery of treatments for immune-related diseases. 05.15.23 Ariceum Therapeutics , a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and UCB , a global biopharmaceutical company, entered into an exclusive, strategic research collaboration agreement to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases. Under the terms of the research collaboration, UCB and Ariceum will utilize each other's technology platforms to enable the discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer. Ariceum to gain access to UCB's expertise to discover novel synthetic macrocyclic peptides using its mRNA-display technology platform, Extreme Diversity. Meanwhile, UCB will benefit from Ariceum's expertise in the field of radiochemistry and labelling technology to enhance its ability to explore how this technology might lead to the discovery of highly differentiated products for immune-related diseases. Both companies will have the opportunity to explore several targets under this research collaboration. Manfred Rüdiger, CEO of Ariceum Therapeutics, said, "We are excited about this strategic collaboration between UCB and Ariceum which aims to broaden Ariceum's pipeline with potentially several new programs at discovery stage. Through this partnership, Ariceum will have access to a unique library that will be used to screen against targets of interest for oncology for which current targeted approaches have failed, while working with UCB on enabling targeted systemic radiotherapy approaches in other areas of severe diseases." Dhaval Patel, chief scientific officer of UCB, said, "The collaboration with Ariceum further enhances our strategic drug discovery capabilities and provides UCB with the opportunity to learn and explore the potential of this modality in our drive to continuously innovate. We look forward to working with Ariceum's scientists and are eager to leverage the technology platforms and disease expertise at each company."

Ariceum Therapeutics Frequently Asked Questions (FAQ)

  • When was Ariceum Therapeutics founded?

    Ariceum Therapeutics was founded in 2021.

  • Where is Ariceum Therapeutics's headquarters?

    Ariceum Therapeutics's headquarters is located at Robert-Rössle-Straße. 10, Berlin.

  • What is Ariceum Therapeutics's latest funding round?

    Ariceum Therapeutics's latest funding round is Series A - II.

  • How much did Ariceum Therapeutics raise?

    Ariceum Therapeutics raised a total of $51.75M.

  • Who are the investors of Ariceum Therapeutics?

    Investors of Ariceum Therapeutics include Pureos Bioventures, Andera Partners, Earlybird Venture Capital, EQT and Healthcap.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.